BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

635 related articles for article (PubMed ID: 22710578)

  • 21. Risk factors for recurrence of clostridium difficile-associated diarrhoea.
    Samie AA; Traub M; Bachmann K; Kopischke K; Theilmann L
    Hepatogastroenterology; 2013 Sep; 60(126):1351-4. PubMed ID: 23262313
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Increasing incidence of clostridium difficile-associated diarrhea in African-American and Hispanic patients: association with the use of proton pump inhibitor therapy.
    Akhtar AJ; Shaheen M
    J Natl Med Assoc; 2007 May; 99(5):500-4. PubMed ID: 17534007
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Vegetative Clostridium difficile survives in room air on moist surfaces and in gastric contents with reduced acidity: a potential mechanism to explain the association between proton pump inhibitors and C. difficile-associated diarrhea?
    Jump RL; Pultz MJ; Donskey CJ
    Antimicrob Agents Chemother; 2007 Aug; 51(8):2883-7. PubMed ID: 17562803
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prevalence and clinical features of Clostridium difficile-associated diarrhea in a tertiary hospital in northern Taiwan.
    Hsu MS; Wang JT; Huang WK; Liu YC; Chang SC
    J Microbiol Immunol Infect; 2006 Jun; 39(3):242-8. PubMed ID: 16783456
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Incidence of Clostridium difficile infection in patients receiving high-risk antibiotics with or without a proton pump inhibitor.
    Gordon D; Young LR; Reddy S; Bergman C; Young JD
    J Hosp Infect; 2016 Feb; 92(2):173-7. PubMed ID: 26616410
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Is over-use of proton pump inhibitors fuelling the current epidemic of Clostridium difficile-associated diarrhoea?
    Cunningham R; Dial S
    J Hosp Infect; 2008 Sep; 70(1):1-6. PubMed ID: 18602190
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Proton pump inhibitors and risk for recurrent Clostridium difficile infection.
    Linsky A; Gupta K; Lawler EV; Fonda JR; Hermos JA
    Arch Intern Med; 2010 May; 170(9):772-8. PubMed ID: 20458084
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Administration of proton pump inhibitors in critically ill medical patients is associated with increased risk of developing Clostridium difficile-associated diarrhea.
    Buendgens L; Bruensing J; Matthes M; Dückers H; Luedde T; Trautwein C; Tacke F; Koch A
    J Crit Care; 2014 Aug; 29(4):696.e11-5. PubMed ID: 24674763
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Past, present, and future therapies for Clostridium difficile-associated disease.
    Surowiec D; Kuyumjian AG; Wynd MA; Cicogna CE
    Ann Pharmacother; 2006 Dec; 40(12):2155-63. PubMed ID: 17148650
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clostridium difficile in cardiac surgery: risk factors and impact on postoperative outcome.
    Crabtree T; Aitchison D; Meyers BF; Tymkew H; Smith JR; Guthrie TJ; Munfakh N; Moon MR; Pasque MK; Lawton J; Moazami N; Damiano RJ
    Ann Thorac Surg; 2007 Apr; 83(4):1396-402. PubMed ID: 17383346
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Established and potential risk factors for Clostridum difficile infection.
    Vaishnavi C
    Indian J Med Microbiol; 2009; 27(4):289-300. PubMed ID: 19736396
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Nosocomial diarrhoea in adult medical patients: the role of Clostridium difficile in a North Italian acute care teaching hospital.
    Sansone S; Aschbacher R; Staffler M; Bombonato M; Girardi F; Larcher C; Wiedermann CJ
    J Prev Med Hyg; 2009 Jun; 50(2):117-20. PubMed ID: 20099443
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Differential risk of Clostridium difficile infection with proton pump inhibitor use by level of antibiotic exposure.
    Stevens V; Dumyati G; Brown J; Wijngaarden E
    Pharmacoepidemiol Drug Saf; 2011 Oct; 20(10):1035-42. PubMed ID: 21833992
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clostridium difficile-associated diarrhoea in patients with human immunodeficiency virus infection: a case-control study.
    Tumbarello M; Tacconelli E; Leone F; Cauda R; Ortona L
    Eur J Gastroenterol Hepatol; 1995 Mar; 7(3):259-63. PubMed ID: 7743309
    [TBL] [Abstract][Full Text] [Related]  

  • 35. How much do PPIs contribute to C. difficile infections?
    Leontiadis GI; Miller MA; Howden CW
    Am J Gastroenterol; 2012 Jul; 107(7):1020-1. PubMed ID: 22764024
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Probiotics for the prevention of Clostridium difficile-associated diarrhea: a systematic review and meta-analysis.
    Johnston BC; Ma SS; Goldenberg JZ; Thorlund K; Vandvik PO; Loeb M; Guyatt GH
    Ann Intern Med; 2012 Dec; 157(12):878-88. PubMed ID: 23362517
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Probiotics for prevention of antibiotic-associated diarrhea and Clostridium difficile-associated disease in hospitalized adults--a meta-analysis.
    Avadhani A; Miley H
    J Am Acad Nurse Pract; 2011 Jun; 23(6):269-74. PubMed ID: 21649768
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Proton pump inhibitor therapy and potential long-term harm.
    Corleto VD; Festa S; Di Giulio E; Annibale B
    Curr Opin Endocrinol Diabetes Obes; 2014 Feb; 21(1):3-8. PubMed ID: 24310148
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clostridium difficile-associated diarrhea and chronic renal insufficiency.
    Yousuf K; Saklayen MG; Markert RJ; Barde CJ; Gopalswamy N
    South Med J; 2002 Jul; 95(7):681-3. PubMed ID: 12144071
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Proton pump inhibitor use and association with spontaneous bacterial peritonitis in patients with cirrhosis and ascites.
    Siple JF; Morey JM; Gutman TE; Weinberg KL; Collins PD
    Ann Pharmacother; 2012 Oct; 46(10):1413-8. PubMed ID: 23032651
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 32.